Ophthalmic Medications

Ophthalmic pharmacotherapy includes medications used to lubricate the ocular surface, suppress allergic or inflammatory symptoms, treat infection, reduce redness, lower intraocular pressure, and assist with diagnosis. Because many benign eye complaints resemble conditions that can threaten vision, safe prescribing also requires recognizing when topical treatment is inappropriate and urgent ophthalmic evaluation is needed.

The assigned pharmacotherapy chapter emphasizes that some common ophthalmic disorders are self-limited while others can result in permanent visual impairment. Medication selection therefore depends on both the likely disorder and whether the presentation is appropriate for primary-care treatment (Hilaire & Hornecker, 2026).

Ophthalmic Administration

Correct administration improves local drug delivery and reduces contamination and systemic absorption. Patients should wash their hands before and after instilling medication, avoid touching the dropper tip to the eye or any other surface, and remove contact lenses when directed.

After instilling an ophthalmic drop, the eye can be gently closed and pressure applied over the nasolacrimal duct for approximately 2–3 minutes. This punctal occlusion decreases drainage into the nasopharynx, reduces systemic absorption, and may increase ocular drug availability (Hilaire & Hornecker, 2026).

Contact lenses should generally be removed before instilling ophthalmic medication. Product-specific reinsertion intervals should be followed. Ointments may blur vision and are often better suited to bedtime or situations in which longer ocular contact is desirable.

Ocular Lubricants and Artificial Tears

Artificial tears are a mainstay of therapy for dry eye. They increase tear-film volume and viscosity and provide symptomatic lubrication of the ocular surface. When artificial tears are required more than four times daily, or when a patient develops sensitivity to preservatives, a preservative-free formulation is preferred. Gel and ointment formulations provide longer relief but may temporarily blur vision, making ointments particularly useful at bedtime (Hilaire & Hornecker, 2026).

Environmental and behavioral measures can improve dry eye and should accompany medication therapy. These include increasing blink frequency, taking breaks from prolonged screen use or reading, reducing air drafts, using humidification when appropriate, stopping smoking, practicing eyelid hygiene, and applying warm compresses when indicated. Medication review is also important because several systemic drugs can worsen dry eye, including anticholinergics, antihistamines, antidepressants, beta-blockers, diuretics, and systemic retinoids (Hilaire & Hornecker, 2026).

Prescription Therapy for Dry Eye

Cyclosporine

Topical cyclosporine reduces ocular-surface inflammation and can increase tear production in selected patients. Improvement is gradual rather than immediate, and several months may be required for full benefit. It should not be presented as an acute-relief medication (Hilaire & Hornecker, 2026).

Lifitegrast

Lifitegrast is an antagonist of lymphocyte function-associated antigen-1 (LFA-1). By interfering with the interaction between LFA-1 and intercellular adhesion molecule-1, it reduces inflammatory signaling at the ocular surface. Common adverse effects include ocular irritation, altered taste, and reduced visual acuity. Like cyclosporine, it is intended for ongoing treatment rather than immediate symptom relief (Hilaire & Hornecker, 2026).

Perfluorohexyloctane

Perfluorohexyloctane is a newer treatment for signs and symptoms of dry-eye disease that targets tear evaporation. Blurred vision is a reported adverse effect. Contact lenses should be removed before administration and should not be reinserted for at least 30 minutes (Hilaire & Hornecker, 2026).

Topical Corticosteroids

Short courses of topical corticosteroids such as loteprednol may be used for selected, diagnosed ocular-surface inflammatory conditions, but they should not be initiated empirically for an undifferentiated red eye in primary care. When an ocular corticosteroid appears necessary, ophthalmology-directed diagnosis and monitoring are generally appropriate. These agents can increase intraocular pressure, delay epithelial healing, mask or worsen infection, and produce local immunosuppression. In particular, inappropriate corticosteroid use can worsen herpetic, fungal, or Acanthamoeba disease; corticosteroids used in bacterial keratitis should be directed by an ophthalmologist (F.A. Davis Company, 2021; Hilaire & Hornecker, 2026).

Ocular Antiallergic Medications

Ocular allergy can be treated with artificial tears, antihistamines, mast-cell stabilizers, combination agents, selected vasoconstrictors, NSAIDs, and, in more severe cases, topical corticosteroids. Treatment generally begins with allergen avoidance, cold compresses, and artificial tears (Hilaire & Hornecker, 2026).

Topical Antihistamines

Topical H1 antihistamines provide rapid relief of ocular itching and allergic symptoms. Agents include azelastine, epinastine, ketotifen, olopatadine, alcaftadine, and bepotastine. Topical therapy is generally preferred before oral antihistamines when the complaint is predominantly ocular because it provides direct treatment while limiting systemic adverse effects (Hilaire & Hornecker, 2026).

Antihistamine/Mast-Cell Stabilizer Combinations

Several ophthalmic agents provide both antihistamine and mast-cell-stabilizing effects. Ketotifen and olopatadine are examples. The antihistamine component provides relatively rapid relief while mast-cell stabilization helps suppress subsequent mediator release. These agents are particularly useful for intermittent ocular allergy flares, and ketotifen provides an OTC option (Phan & Daines, 2026).

Mast-Cell Stabilizers

Agents such as cromolyn and lodoxamide inhibit mast-cell degranulation. Their primary role is prevention rather than immediate symptom relief. Full response can take weeks, making them poorly suited to a patient seeking rapid relief from an acute episode (Hilaire & Hornecker, 2026).

Ophthalmic NSAIDs and Vasoconstrictors

Ketorolac is a topical NSAID approved for ocular itching associated with allergic conjunctivitis and is also one of several ophthalmic NSAIDs used in selected inflammatory or procedural settings. These indications should not be generalized to routine undifferentiated red-eye management (Hilaire & Hornecker, 2026).

Ophthalmic vasoconstrictors such as naphazoline, tetrahydrozoline, phenylephrine, and oxymetazoline constrict conjunctival blood vessels and temporarily reduce redness. They do not treat the underlying cause of inflammation. Prolonged or excessive use can cause rebound redness, and narrow-angle glaucoma is an important precaution (F.A. Davis Company, 2021).

Antiglaucoma Medications

The Week 3 course material includes antiglaucoma medications even though glaucoma treatment is generally managed by ophthalmology. The major pharmacologic goal is reduction of intraocular pressure by decreasing aqueous humor production, increasing aqueous outflow, or both (F.A. Davis Company, 2021).

Prostaglandin analogs such as latanoprost primarily increase uveoscleral outflow and are commonly used because of strong intraocular-pressure reduction and once-daily dosing. Expected local effects include conjunctival hyperemia, increased eyelash growth, and gradual darkening of iris or periocular pigmentation. Beta blockers such as timolol reduce aqueous humor production but can produce clinically important systemic bradycardia, hypotension, heart block, and bronchospasm after topical administration, making pulmonary and cardiovascular history relevant to medication reconciliation (Blanchard et al., 2026).

Alpha-2 agonists such as brimonidine reduce aqueous production and can also increase uveoscleral outflow; dry mouth, fatigue, and ocular allergy can limit use. Topical carbonic anhydrase inhibitors such as dorzolamide and brinzolamide reduce aqueous production and commonly cause local irritation or taste disturbance. Miotics such as pilocarpine increase conventional trabecular outflow through ciliary-muscle contraction but can cause miosis, accommodative symptoms, and brow ache. Rho-kinase inhibition with netarsudil increases conventional outflow through the trabecular meshwork and Schlemm canal; conjunctival hyperemia and corneal verticillata are characteristic adverse effects (Blanchard et al., 2026).

Individual drug selection depends on glaucoma type, target intraocular pressure, comorbidities, contraindications, response, adherence, and specialist management. These class distinctions are most useful in Week 3 for recognizing medication-related systemic effects and avoiding unsafe changes to specialist-directed therapy.

Topical administration does not eliminate systemic pharmacology. Ophthalmic antiglaucoma medications can be absorbed through the nasolacrimal system in clinically meaningful amounts, contributing to adverse effects and drug interactions. Punctal occlusion can reduce systemic exposure. This is particularly relevant with beta-blocking or adrenergic medications in patients with cardiovascular or pulmonary comorbidity (F.A. Davis Company, 2021; Hilaire & Hornecker, 2026).

For Week 3, the high-yield prescribing principle is to recognize the major classes, understand that systemic effects are possible, and avoid casually altering specialist-directed glaucoma therapy when evaluating an unrelated eye complaint.

Ophthalmic Anti-Infectives

Topical ophthalmic antibiotics are used for selected bacterial infections of the ocular surface. Drug choice depends on the suspected pathogen, severity, age, contact-lens use, and whether disease involves the conjunctiva alone or extends to the cornea. Most topical anti-infectives produce relatively low systemic exposure, but local irritation, hypersensitivity, and superinfection can occur (F.A. Davis Company, 2021).

For uncomplicated bacterial conjunctivitis, topical antibiotic selection depends on age, severity, formulation preference, and contact-lens use. Contact lenses increase concern for Pseudomonas and for keratitis rather than uncomplicated conjunctivitis. Detailed diagnosis-specific antimicrobial selection and stewardship are addressed on the Conjunctivitis page (Hilaire & Hornecker, 2026).

Other Ophthalmic Anti-Infective Applications

Blepharitis

Blepharitis often overlaps with meibomian-gland dysfunction and ocular-surface irritation. Lid hygiene is foundational. When bacterial involvement is clinically significant, topical antibiotic therapy may be added. The assigned 2026 chapter specifically notes that concurrent blepharitis should prompt addition of a lid-hygiene regimen when treating bacterial conjunctivitis (Hilaire & Hornecker, 2026).

Neonatal and Lacrimal-System Infections

The course PowerPoint also includes ophthalmia neonatorum and dacryostenosis among ophthalmic anti-infective applications. The important prescribing distinction is that gonococcal and chlamydial neonatal conjunctivitis are not routine topical “pink eye” problems: gonococcal disease requires systemic ceftriaxone, and neonatal chlamydial infection requires systemic therapy. These presentations warrant age-specific evaluation rather than empiric outpatient topical treatment based only on discharge (F.A. Davis Company, 2021).

Corneal Abrasions and Fluorescein

Corneal abrasions are epithelial defects that commonly heal within 24–72 hours depending on depth. Uncomplicated abrasions should not be routinely patched. In non-contact-lens wearers, prophylactic topical antibiotics active against Staphylococcus, such as erythromycin ointment or trimethoprim-polymyxin B, are reasonable options. Contact-lens wearers require antipseudomonal coverage and closer follow-up because of bacterial keratitis risk (Hilaire & Hornecker, 2026).

Fluorescein is a diagnostic dye used to identify defects in the corneal epithelium. An epithelial defect fluoresces under appropriate blue-light illumination while an intact corneal surface does not retain the dye. Branching or dendritic staining can suggest herpetic keratitis and should prompt ophthalmic evaluation rather than routine treatment as uncomplicated conjunctivitis (F.A. Davis Company, 2021; Yeu & Hauswirth, 2020).

Hordeolum

A hordeolum is an infection of an eyelid gland, commonly caused by Staphylococcus aureus. Warm compresses are a major component of treatment. Antibiotics are generally not required for an uncomplicated external hordeolum. Internal or persistent lesions may require antimicrobial therapy or ophthalmology referral, particularly when a large lesion does not resolve and drainage may be necessary (Hilaire & Hornecker, 2026).

Red Flags and Referral

Primary-care treatment should stop when the presentation suggests a potentially vision-threatening disorder. Immediate ophthalmic evaluation is warranted for acute angle-closure glaucoma, acute chemical burns, acute vision loss, significant ocular trauma, foreign body, orbital cellulitis, retinal detachment, sudden proptosis, and other high-risk presentations. Corneal ulceration requires prompt evaluation (Hilaire & Hornecker, 2026).

Visual loss, moderate-to-severe pain, severe purulent discharge, photophobia, or corneal involvement also warrant escalation. A contact-lens wearer with a painful red eye deserves particular caution because bacterial keratitis can progress rapidly (Yeu & Hauswirth, 2020).

Chemical Exposure

Chemical eye exposure is an emergency in which irrigation takes priority over a complete examination. Irrigation should begin immediately with any readily available nontoxic fluid and should not be delayed while transportation is arranged or the exact chemical is identified. In clinical care, irrigation is continued until conjunctival-fornix pH returns to the physiologic range, approximately 7.0–7.4, and remains stable after irrigation is stopped; large volumes may be required. Retained particulate material should be sought and removed because it can continue to alter ocular pH (Rho et al., 2026; Hilaire & Hornecker, 2026).

Clinical Prescribing Perspective

Ophthalmic prescribing begins with determining whether the patient’s complaint is appropriate for topical treatment at all. Mild itching and watery eyes may be treated with an ocular antihistamine or artificial tears. Mild dry-eye symptoms may respond to environmental modification and lubricants. A contact-lens wearer with a painful red eye, photophobia, or reduced visual acuity requires a different level of concern because corneal infection can threaten vision.

Medication selection should integrate the likely diagnosis, severity, contact-lens use, corneal involvement, visual acuity, pain, systemic comorbidity, and the patient’s ability to administer the product safely.

High-Yield Distinctions

  • Artificial tears: first-line symptomatic therapy for many patients with dry eye and useful for allergen dilution.
  • Preservative-free tears: preferred when artificial tears are needed more than four times daily or preservatives cause irritation.
  • Cyclosporine and lifitegrast: chronic anti-inflammatory dry-eye therapies rather than immediate-relief medications.
  • Topical antihistamines: rapid treatment for ocular allergy.
  • Mast-cell stabilizers: preventive rather than rapid-relief medications.
  • Ophthalmic vasoconstrictors: temporarily reduce redness but can cause rebound hyperemia with excessive use.
  • Antiglaucoma medications can produce systemic effects despite topical administration; punctal occlusion can reduce systemic absorption.
  • Topical ocular corticosteroids should not be started empirically for an undifferentiated red eye; when they appear necessary, ophthalmology-directed diagnosis and monitoring are generally appropriate because corticosteroids can raise intraocular pressure, delay healing, and worsen some infections.
  • Fluorescein is diagnostic rather than therapeutic and highlights corneal epithelial defects.
  • Pain, photophobia, vision loss, severe purulence, or corneal involvement are red flags for urgent evaluation.

Content last reviewed:

References

Blanchard, C., Fisher, R., Moore, D. B., Owaidhah, O. A., & Shiuey, E. (2026, February 11). Review of topical glaucoma medications. EyeWiki. https://eyewiki.org/Review_of_Topical_Glaucoma_Medications

F.A. Davis Company. (2021). Drugs used to treat eye and ear disorders [PowerPoint slides].

Hilaire, M. L., & Hornecker, J. R. (2026). Minor ophthalmic and otic disorders. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed.). McGraw Hill.

Phan, H., & Daines, M. (2026). Allergic rhinitis. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed.). McGraw Hill.

Rho, J. E., Jerkins, B., Fowler, B. T., Dryden, S. C., Murchison, A., Justin, G. A., Yen, M. T., Giacometti, J., Armstrong, G. W., & Bair, H. (2026, September 14). Pre-ophthalmologist management of eye trauma. EyeWiki. https://eyewiki.org/Pre-Ophthalmologist_Management_of_Eye_Trauma Yeu, E., & Hauswirth, S. (2020). A review of the differential diagnosis of acute infectious conjunctivitis: Implications for treatment and management. Clinical Ophthalmology, 14, 805–813. https://doi.org/10.2147/OPTH.S236571s of acute infectious conjunctivitis: Implications for treatment and management. Clinical Ophthalmology, 14, 805–813. https://doi.org/10.2147/OPTH.S236571